| Literature DB >> 36168381 |
Gaurav Sahu1, Shiv H Joshi2, Sarthak Mendiratta1.
Abstract
Background In this study, we aimed to compare the imaging findings between coronavirus disease (COVID-19) patients with well-controlled, poorly-controlled, and non-diabetic patients and subsequently find any relation between haemoglobin A1c (HbA1c) levels and high-resolution chest computed tomography (HRCT) chest score. Methodology A total of 200 individuals with coexisting COVID-19 and type 2 diabetes mellitus were included in this retrospective cohort study. Based on their HbA1c levels, patients were divided into three groups. The imaging data and laboratory values were obtained from the online medical records of the patients. In addition, the chest computed tomography (CT) score was evaluated as the sum of individual scores from five lung lobes: scores of 0, 1, 2, 3, 4, and 5 were assigned to each lobe. Any peripheral opacification pattern was noted. Haemoglobin A1c (HbA1c) levels and HRCT scores were then analysed by multiple linear regression models using R software. Results The prevalence of diabetes in the study population was 71.5%. Of this, 56 patients had well-controlled diabetes (28%) and 87 patients had poorly controlled diabetes (43.5%); 126 (63%) patients were male and the median age was 54.45 years (95% CI: 54.45 ± 15.53). We found that diabetes status, co-presence of ground-glass appearance with mixed consolidation, and consolidation and reverse halo sign in the HRCT findings were significant predictors of the HRCT scores in patients with COVID-19. Conclusions The presence of any co-morbidities should be viewed as a high-risk case of COVID-19. Diabetes status is significantly associated with the severity of HRCT findings in lab-confirmed COVID-19 infection. Therefore, it is important to prioritise the patients who have COVID-19 along with diabetes.Entities:
Keywords: computed tomography; covid-19; diabetes; hba1c; hrct score
Year: 2022 PMID: 36168381 PMCID: PMC9506668 DOI: 10.7759/cureus.28371
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Socio-demographic variables and diabetic status of the patients.
SD: Standard deviation.
| Variables | Total | Non-diabetic | Prediabetic | Diabetic | P-value |
| n (%) | 200 (100%) | 57 (28.5%) | 56 (28.0%) | 87 (43.5%) | |
| Age (years) | |||||
| Mean±SD | 54.45±15.53 (18-75) | 56.42 ±15.98 (18-75) | 57.30±14.56 (32-75) | 51.33±15.44 (18-75) | 0.04 |
| Gender | |||||
| Male, n (%) | 126 (63%) | 38 (33.33%) | 37 (66.07%) | 51 (58.62%) | 0.44 |
| Female, n (%) | 74 (37%) | 19 (66.67%) | 19 (33.93%) | 36 (41.38%) | |
Comparison between high resolution computed tomography (HRCT) findings and clinical diabetic status of the patients.
HRCT: high-resolution computed tomography; RUL: right upper lobe; RML: right middle lobe; RLL: right lower lobe; LUL: left upper lobe; LLL: left lower lobe; GGO: ground-glass opacification.
| Variables | Total | Non-diabetic | Prediabetic | Diabetic | P-value |
| n (%) | 200 (100%) | 57 (28.5%) | 56 (28.0%) | 87 (43.5%) | |
| Median total HRCT Score | 14 (1-25) | 6 (2-22) | 14 (8-25) | 16 (1-25) | <0.001* |
| HRCT score according to lobe | |||||
| RUL median | 3 (0-5) | 1±0.86 (0-4) | 3±1.05 (0-5) | 3±0.91 (2-5) | <0.0001* |
| RML median | 3 (0-5) | 1±0.91 (0-4) | 3±1.09 (0-5) | 3±0.95 (1-5) | <0.0001* |
| RLL median | 3 (0-5) | 1±1.38 (0-5) | 4±1.26 (0-5) | 4±1.18 (0-5) | <0.0001* |
| LUL median | 3 (0-5) | 1±1.23 (0-5) | 3±1.47 (0-5) | 3±1.23 (0-5) | <0.0001* |
| LLL median | 2 (0-5) | 1±1.09 (0-5) | 2±1.54 (0-5) | 3±1.28 (0-5) | <0.0001* |
| Predominant CT pattern | |||||
| GGO, n (%) | 157 (78.50%) | 50 (87.72%) | 43 (76.79%) | 64 (73.56%) | <0.001* |
| Consolidation, n (%) | 45 (22.50%) | 1 (1.75%) | 9 (16.07%) | 35 (40.23%) | |
| GGO/Consolidation (mixed), n (%) | 74 (37.00%) | 4 (7.02%) | 19 (33.93%) | 51 (58.62%) | <0.001* |
| Crazy pavement, n (%) | 14 (7.00%) | 0 (0.00%) | 2 (3.57%) | 12 (13.79%) | |
| Reverse halo sign, n (%) | 4 (2.00%) | 0 (0.00%) | 2 (3.57%) | 2 (2.30%) | |
Multiple linear regression analysis model 1.
GGO: ground-glass opacification.
Significant codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1
Residual standard error: 4.13 on 195 degrees of freedom
Multiple R-squared: 0.5226, Adjusted R-squared: 0.5128
F-statistic: 53.36 on 4 and 195 degrees of freedom, P-value: < 2.2e-16
| Model 1 | |||||
| Coefficients: | Estimate Std | Error | t value | Pr(>|t|) | |
| (Intercept) | 14.1680 | 0.5945 | 23.833 | < 2e-16 | *** |
| Diabetic-non-diabetic | -7.4021 | 0.7855 | -9.423 | < 2e-16 | *** |
| Diabetic-pre-diabetic | -0.5368 | 0.7292 | -0.736 | 0.4625 | |
| GGO and consolidation mixed | 3.0853 | 0.6866 | 4.494 | 1.2e-05 | *** |
| Reverse halo sign | 5.5151 | 2.1302 | 2.589 | 0.0104 | * |
Multiple linear regression analysis model 2.
GGO: ground-glass opacification.
Significant codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1
Residual standard error: 4. 793 on 195 degrees of freedom
Multiple R-squared: 0.3569, Adjusted R-squared: 0.3437
F-statistic: 27.05 on 4 and 195 degrees of freedom, P-value < 2.2e-16
| Model 2 | |||||
| Coefficients: | Estimate Std | Error | t value | Pr(>|t|) | |
| (Intercept) | 6.5329 | 1.1589 | 5.637 | 6.00e-08 | *** |
| HbA1c levels | 0.6346 | 0.1780 | 3.565 | 0.000458 | *** |
| GGO and consolidation mixed | 4.3966 | 0.7784 | 5.648 | 5.68e-08 | *** |
| Consolidation | 2.2557 | 0.8503 | 2.653 | 0.008642 | ** |
| Reverse Halo | 6.8040 | 2.4761 | 2.748 | 0.006561 | ** |